![Michel Gardet](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Michel Gardet is currently a Director at Phagenesis Ltd. He was formerly a Director at Glycom A and Global Head-Business Operations at Nestle Health Science SA.
Actieve functies van Michel Gardet
| Bedrijven | Functie | Begin |
|---|---|---|
Phagenesis Ltd.
 Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat patients suffering from neurogenic dysphagia | Directeur/Bestuurslid | - |
Eerdere bekende functies van Michel Gardet
| Bedrijven | Functie | Einde |
|---|---|---|
Nestle Health Science SA
 Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Manufactures nutritional and supplement health products | Operationeel Directeur | - |
Glycom A/S
 Glycom A/S BiotechnologyHealth Technology Engages in the development, synthesis, and commercialization of human milk oligosaccharides | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
10
Eerstegraads connecties
3
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
Glycom A/S
Glycom A/S BiotechnologyHealth Technology Engages in the development, synthesis, and commercialization of human milk oligosaccharides | Health Technology |
Phagenesis Ltd.
Phagenesis Ltd. Pharmaceuticals: MajorHealth Technology Develops novel therapies to treat patients suffering from neurogenic dysphagia | Health Technology |
Nestle Health Science SA
Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Manufactures nutritional and supplement health products | Health Technology |
